Publication
Tiotropium improves FEV1 in patients with COPD irrespective of smoking status
| dc.contributor.author | Moita, J | |
| dc.contributor.author | Bárbara, C | |
| dc.contributor.author | Cardoso, J | |
| dc.contributor.author | Costa, R | |
| dc.contributor.author | Sousa, M | |
| dc.contributor.author | Ruiz, J | |
| dc.contributor.author | Santos, ML | |
| dc.date.accessioned | 2012-08-29T10:25:48Z | |
| dc.date.available | 2012-08-29T10:25:48Z | |
| dc.date.issued | 2000 | |
| dc.description.abstract | This study evaluated whether the effect of tiotropium on the change in trough forced expiratory volume in 1s (FEV1), vs. placebo, is affected by smoking status. In a 3-month, double-blind study in 31 centres in Portugal, 311 (289 completed) patients were randomised to tiotropium 18 microg once daily or placebo. Baseline mean (standard deviation (SD)) FEV1 was 1.11 (0.39) l in the tiotropium group and 1.13 (0.39) l in the placebo group. Patients had an average smoking history of 55 (25.7) pack-years; 80 (26%) were smokers and 224 (74%) were ex-smokers. The primary end-point was change in morning pre-dose (i.e. trough) FEV1 after 12 weeks. Trough FEV1 at 12 weeks was significantly improved with tiotropium vs. placebo: the difference in means was 102 ml, P=0.0011, 95% confidence interval (CI) (41, 164). The difference in means in smokers was 138 ml, P=0.0105, CI (32, 244); in ex-smokers it was 66 ml, P=0.0375, CI (3, 129). The difference between smokers and ex-smokers was not statistically significant (P=0.6982) and may be due to greater variability and differences in disease severity. The significant improvement in lung function in patients treated with tiotropium vs. placebo in both smokers and ex-smokers suggests that tiotropium is an effective and well-tolerated therapy in chronic obstructive pulmonary disease (COPD), regardless of smoking status. | por |
| dc.identifier.citation | Pulm Pharmacol Ther. 2008;21(1):146-51 | por |
| dc.identifier.issn | 1094-5539 | |
| dc.identifier.uri | http://hdl.handle.net/10400.10/675 | |
| dc.language.iso | eng | por |
| dc.peerreviewed | yes | por |
| dc.publisher | Academic Press | por |
| dc.subject | Broncodilatadores | por |
| dc.subject | Doença pulmonar obstrutiva crónica | por |
| dc.subject | Bronchodilator agents | por |
| dc.subject | Chronic obstructive pulmonary disease | por |
| dc.subject | Tiotropium | por |
| dc.title | Tiotropium improves FEV1 in patients with COPD irrespective of smoking status | por |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.conferencePlace | London | por |
| oaire.citation.endPage | 151 | por |
| oaire.citation.startPage | 146 | por |
| oaire.citation.title | Pulmonary pharmacology and therapeutics | por |
| oaire.citation.volume | 21 | por |
| rcaap.rights | openAccess | por |
| rcaap.type | article | por |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Pulmonary Pharmacology & Therapeutics 21 (2008) 146–151.pdf
- Size:
- 158.78 KB
- Format:
- Adobe Portable Document Format
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: